RASAGILINE
Drug
H. Lundbeck A S
Total Payments
$22,557
Transactions
8
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1,697 | 1 | 1 |
| 2018 | $13,169 | 4 | 1 |
| 2017 | $7,692 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $8,619 | 2 | 38.2% |
| Unspecified | $7,692 | 3 | 34.1% |
| Honoraria | $6,197 | 2 | 27.5% |
| Food and Beverage | $50.00 | 1 | 0.2% |
Payments by Type
General
$14,866
5 transactions
Research
$7,692
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TVP-1012/PM106 | Teva Pharmaceuticals USA, Inc. | $7,692 | 0 |
Ad
Manufacturing Companies
- H. Lundbeck A S $14,866
- Teva Pharmaceuticals USA, Inc. $7,692
Product Information
- Type Drug
- Total Payments $22,557
- Total Doctors 2
- Transactions 8
About RASAGILINE
RASAGILINE is a drug associated with $22,557 in payments to 2 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is H. Lundbeck A S.
Payment data is available from 2017 to 2019. In 2019, $1,697 was paid across 1 transactions to 1 doctors.
The most common payment nature for RASAGILINE is "Travel and Lodging" ($8,619, 38.2% of total).
RASAGILINE is associated with 1 research study, including "TVP-1012/PM106" ($7,692).